Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Hematol
Hauptverfasser: Cheson, Bruce D., Trask, Peter C., Gribben, John G., Dimier, Natalie, Kimby, Eva, Lugtenburg, Pieternella J., Thieblemont, Catherine, Wassner-Fritsch, Elisabeth, Launonen, Aino, Sehn, Laurie H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2016
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226995/
https://ncbi.nlm.nih.gov/pubmed/27900446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-016-2878-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge